Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $22.12M rose 150.6% year over year, behind the +187.8% change in trailing-twelve-month net income. Sequentially, it rose 63.3% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Net income amounted to 3.4% of revenue in FY2025, down 2.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $86.68M (+76.1%) for the fiscal year ending Dec 2026, a slowdown from the +169.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $22.12M+63.3% QoQ
- Last fiscal yearDec 2025
- $49.22M+169.3% YoY
- LTMJun 2026
- $66.52M+187.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +150.6% | +109.6% | -41.0 pp |
| 1 year | +169.3% | +76.1% | -93.2 pp |
| 3-year CAGR | -0.3% | +29.9% | +30.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 49.22M USD
- Year-over-year change
- +169.3%
- 4-year CAGR
- +14.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.22M | +169.3% |
| FY2024 | 2024-12-31 | (71.03M) | -288.3% |
| FY2023 | 2023-12-31 | 37.72M | -24.0% |
| FY2022 | 2022-12-31 | 49.66M | +75.3% |
| FY2021 | 2021-12-31 | 28.33M | — |
Net Income vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 net income of $66.52M is the 10th largest of the 11 companies compared; the peer median is $41.9M.
- Its year-over-year change of +187.8% is the 3rd highest of 11, against a peer median of +30.4%.
- Net income amounts to 4.5% of revenue for GRDN, versus a peer median of 28.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.21B | +237.6% | — | 45.6% | |
| LTM Sep 2026 | $1.18B | +848.8% | +35.4% | — | |
| LTM Sep 2026 | $150.09M | -7.5% | +38.3% | 7.7% | |
| LTM Sep 2026 | $130.2M | +67.6% | -14.0% | 28.3% | |
| LTM Sep 2026 | $116.02M | +12.2% | +83.1% | 7.3% | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $102.47M | +13.6% | +3.1% | 31.8% | |
| LTM Jun 2026 | $75.13M | -11.2% | -36.0% | 12.2% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $66.52M | +187.8% | -0.3% | 4.5% |
| LTM Jun 2026 | $8.67M | -91.5% | — | 7.2% | |
| Peer median (excluding GRDN) | $41.9M | +30.4% | +23.5% | 28.3% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 28.33M | 49.66M | 37.72M | (71.03M) | 49.22M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3.07M |
| Stock-Based Compensation | 13.03M | (3.38M) | (6.09M) | 131.49M | 13.85M |
| Change in Working Capital | (1.47M) | (18.72M) | 15.6M | (29.41M) | 6.38M |
| Accounts Receivables | (7.71M) | (16.79M) | (14.3M) | (25.49M) | (8.55M) |
| Inventory | (240K) | (8.12M) | 4.43M | (1.15M) | (877K) |
| Accounts Payables | 9.78M | 13.37M | 6.3M | 13.23M | 16.4M |
| Other Working Capital | (3.3M) | (7.17M) | 19.18M | (16M) | (586K) |
| Other Non-Cash Items | 2.08M | 4.4M | 5.35M | 7.14M | 5.43M |
| Operating Cash Flow | 58.5M | 48.52M | 70.82M | 57.96M | 100.29M |
| Capital Expenditures | (9.28M) | (16.77M) | (14.56M) | (16.37M) | (19.58M) |
| Acquisitions (Net) | (4.4M) | (2M) | (985K) | (14.71M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 535K | 874K | 2.1M | 671K | (12.68M) |
| Investing Cash Flow | (13.15M) | (17.9M) | (13.44M) | (30.41M) | (32.26M) |
| Debt Repayment | (6.1M) | (2.8M) | (2.89M) | (36.48M) | (4.98M) |
| Common Stock Issued | 0 | 0 | 0 | 119.78M | 27.45M |
| Common Stock Repurchased | 0 | 0 | 0 | (55.18M) | (29.04M) |
| Dividends Paid | (17.36M) | (30.8M) | (38.42M) | (35.75M) | 0 |
| Other Financing Activities | (13.34M) | (11.42M) | (15.92M) | (16.02M) | (497K) |
| Financing Cash Flow | (36.79M) | (45.03M) | (57.23M) | (23.65M) | (7.07M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.56M | (14.41M) | 145K | 3.91M | 60.96M |
| Free Cash Flow | 49.22M | 31.75M | 56.26M | 41.59M | 80.71M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.